IL129445A0 - Improvements in or relating to diagnostic/therapeutic agents - Google Patents

Improvements in or relating to diagnostic/therapeutic agents

Info

Publication number
IL129445A0
IL129445A0 IL12944597A IL12944597A IL129445A0 IL 129445 A0 IL129445 A0 IL 129445A0 IL 12944597 A IL12944597 A IL 12944597A IL 12944597 A IL12944597 A IL 12944597A IL 129445 A0 IL129445 A0 IL 129445A0
Authority
IL
Israel
Prior art keywords
diagnostic
relating
therapeutic agents
gas
reporter
Prior art date
Application number
IL12944597A
Other languages
English (en)
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622366.4A external-priority patent/GB9622366D0/en
Priority claimed from GBGB9622369.8A external-priority patent/GB9622369D0/en
Priority claimed from GBGB9702195.0A external-priority patent/GB9702195D0/en
Priority claimed from GBGB9708265.5A external-priority patent/GB9708265D0/en
Priority claimed from GBGB9711837.6A external-priority patent/GB9711837D0/en
Priority claimed from GBGB9711839.2A external-priority patent/GB9711839D0/en
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of IL129445A0 publication Critical patent/IL129445A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
IL12944597A 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents IL129445A0 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB9622366.4A GB9622366D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9622369.8A GB9622369D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9702195.0A GB9702195D0 (en) 1997-02-04 1997-02-04 Improvements in or relating to diagnostic/therapeutic agents
GBGB9708265.5A GB9708265D0 (en) 1997-04-24 1997-04-24 Contrast agents
US4926397P 1997-06-06 1997-06-06
US4926497P 1997-06-06 1997-06-06
US4926697P 1997-06-06 1997-06-06
GBGB9711837.6A GB9711837D0 (en) 1997-06-06 1997-06-06 Improvements in or relating to diagnostic / therapeutic agents
GBGB9711839.2A GB9711839D0 (en) 1997-06-06 1997-06-06 Improvements in or relating to diagnostic/therapeutic agents
PCT/GB1997/002953 WO1998018500A2 (fr) 1996-10-28 1997-10-28 Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant

Publications (1)

Publication Number Publication Date
IL129445A0 true IL129445A0 (en) 2000-02-29

Family

ID=27576371

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12944597A IL129445A0 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents

Country Status (15)

Country Link
EP (1) EP1007101B1 (fr)
JP (1) JP2001511765A (fr)
KR (1) KR20000052830A (fr)
CN (1) CN1238700A (fr)
AT (1) ATE326242T1 (fr)
AU (1) AU733477B2 (fr)
BG (1) BG103439A (fr)
BR (1) BR9713978A (fr)
CA (1) CA2269985A1 (fr)
DE (1) DE69735901T2 (fr)
HU (1) HUP0000357A2 (fr)
IL (1) IL129445A0 (fr)
NO (1) NO991890L (fr)
NZ (1) NZ335799A (fr)
WO (1) WO1998018500A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503646A (ja) 1996-03-29 2001-03-21 ローレンス バークレー ナショナル ラボラトリィ 過分極化希ガス存在下でのｎｍｒまたはｍｒｉの増強
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
WO1999055837A2 (fr) * 1998-04-28 1999-11-04 Nycomed Imaging As Procedes de separation ameliores
GB9917111D0 (en) * 1999-07-21 1999-09-22 Nycomed Imaging As Method
EP1289565B1 (fr) 2000-06-02 2015-04-22 Bracco Suisse SA Composes pour le ciblage des cellules endotheliales
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US7061237B2 (en) 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
US6652833B2 (en) * 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
CN1243759C (zh) * 2001-03-02 2006-03-01 日本油脂株式会社 聚亚烷基氧改性的磷脂及其制备方法
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US9364569B2 (en) 2003-02-04 2016-06-14 Bracco Suisse S.A. Ultrasound contrast agents and process for the preparation thereof
AU2004308757B2 (en) * 2003-12-22 2010-06-17 Bracco Suisse S.A. Assembly of gas-filled microvesicle with active component for contrast imaging
WO2005063305A1 (fr) * 2003-12-22 2005-07-14 Bracco Research Sa Systeme de microvesicule remplie de gaz pour l'imagerie de contraste
DE602005017475D1 (de) 2004-03-04 2009-12-17 Ge Healthcare As Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie
EP1784228B1 (fr) 2004-08-18 2016-10-05 Bracco Suisse SA Composition à base de microvésicules remplis de gaz pour l'imagerie de contraste
ES2358745T3 (es) 2004-11-22 2011-05-13 Ge Healthcare As Agentes de contraste para señalar matriz extracelular.
JP2006182673A (ja) * 2004-12-27 2006-07-13 Kenji Yamamoto マーカー付き医薬
JP2010513476A (ja) * 2006-12-20 2010-04-30 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
CN101773675B (zh) * 2010-03-05 2012-05-30 中山大学 一种负载液态氟碳的聚合物纳米超声显像囊泡及其制备方法
US20130072854A1 (en) * 2011-09-19 2013-03-21 General Electric Company Microbubble complexes and methods of use
WO2014117232A1 (fr) * 2013-02-04 2014-08-07 Farret Neto Abdo Préparation médicale sous forme de mousse pour la libération prolongée de médicaments et système d'obtention de cette préparation médicale
AU2015300776B2 (en) * 2014-08-07 2021-01-28 The General Hospital Corporation Platelet-targeted microfluidic isolation of cells
NZ733010A (en) 2014-12-31 2023-01-27 Lantheus Medical Imaging Inc Lipid-encapsulated gas microsphere compositions and related methods
IL262647B2 (en) 2016-05-04 2023-03-01 Lantheus Medical Imaging Inc Methods and devices for preparing sharpness factors for ultrasound
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
CN116223678A (zh) * 2023-03-09 2023-06-06 石家庄四药有限公司 一种测定血液中依托咪酯的方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172208B (fr) * 1990-04-02 1993-05-01 Sint Sa
US5780010A (en) * 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US5849727A (en) * 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents

Also Published As

Publication number Publication date
AU733477B2 (en) 2001-05-17
BR9713978A (pt) 2000-05-02
EP1007101A2 (fr) 2000-06-14
NO991890L (no) 1999-06-28
HUP0000357A2 (hu) 2000-06-28
DE69735901D1 (de) 2006-06-22
WO1998018500A2 (fr) 1998-05-07
DE69735901T2 (de) 2007-05-10
WO1998018500A8 (fr) 1999-11-25
WO1998018500A3 (fr) 1998-07-23
BG103439A (en) 2000-01-31
EP1007101B1 (fr) 2006-05-17
ATE326242T1 (de) 2006-06-15
CA2269985A1 (fr) 1998-05-07
JP2001511765A (ja) 2001-08-14
CN1238700A (zh) 1999-12-15
KR20000052830A (ko) 2000-08-25
NZ335799A (en) 2000-11-24
NO991890D0 (no) 1999-04-21
AU4718297A (en) 1998-05-22

Similar Documents

Publication Publication Date Title
IL129445A0 (en) Improvements in or relating to diagnostic/therapeutic agents
WO1998018498A3 (fr) Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant
WO1998018495A3 (fr) Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant
AU4786697A (en) Improvements in or relating to diagnostic/therapeutic agents
DE69417232T2 (de) Intravaginales wirkstoffabgabesystem
AU9383098A (en) Novel targeted contrast agents for diagnostic and therapeutic use
DE69835201D1 (en) Neoglycoproteine
WO1998018501A3 (fr) Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant
IE842539L (en) Conjugates of metallothionein and biologically active¹molecules
CA2308513A1 (fr) Procede et composition permettant d'administrer du zinc ionique a une membrane nasale
AU2526095A (en) Transdermal device for administration through de-epithelialized skin
GR3031897T3 (en) Antifungal nail solution
DE69534599D1 (en) Intrazellulare expression von carboxypeptidase g2 in enzyme-prodrug-therapie
WO2001008711A3 (fr) Microbulles stables comprenant une fraction lipidique encapsulee dans du perfluoropropane et utilisees comme agents de contraste ultrasonores
ZA97657B (en) Ligand directed enzyme prodrug therapy.
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
ES2019025A6 (es) Procedimiento para preparar una composicion farmaceutica liquida de desmopresina.
CA2309653A1 (fr) Utilisation de la proteine h en tant qu'agent cytostatique
PL332035A1 (en) Transdermal therapeutic system including an estriol-containing composition of active substances
HUP9904595A2 (hu) Továbbfejlesztett diagnosztikai és terápiás készítmények
UA13988A (uk) Ветериhарhий аhтигельміhтик
AU2003200048A1 (en) Novel polyamine analogues as therapeutic and diagnostic agents
MX9708111A (es) Lipidos cationicos para terapia genica.

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)

Owner name: GE HEALTHCARE AS

Free format text: FORMER NAME:AMERSHAM HEALTH AS